Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Forecast Highlights Expansion From $3.7 Billion To $6.98 Billion Through 2030
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Forecast Highlighting Growth From $3.7 Billion To $6.98 Billion
The market for adeno-associated virus (AAV) vectors in gene therapy has experienced rapid expansion in recent years. Projected to increase from $3.16 billion in 2025 to $3.7 billion in 2026, this growth reflects a compound annual growth rate (CAGR) of 17.3%. Historical expansion has been driven by progress in viral vector safety, research into rare genetic disorders, successful clinical gene therapy outcomes, regulatory approvals, and investments in academic research.
The market for adeno-associated virus (AAV) vectors in gene therapy is anticipated to experience substantial expansion over the coming years. By 2030, its valuation is projected to reach $6.99 billion, reflecting a compound annual growth rate (CAGR) of 17.2%. This forecasted growth is driven by factors such as the commercialization of gene therapies, rising needs for scalable vector production, the advancement of precision medicine, incentives for orphan drugs, and an increase in global clinical trials. Key trends shaping this period include the broadening of gene augmentation therapies, heightened interest in treatments for rare genetic diseases, the progress of in vivo gene delivery techniques, the scale-up of commercial vector production, and an emphasis on ensuring long-term therapeutic durability.
Download A Free Sample Report For Comprehensive Market Insights:
Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Demand Drivers: What Is Fueling Industry Growth?
The anticipated expansion of the adeno-associated virus (AAV) vectors market within the gene therapy sector is being driven by a growing emphasis on gene-based treatments. These therapies involve modifying or manipulating genes at the molecular level to prevent, treat, or cure diseases. Progress in genetic research is fueling this heightened focus, as it improves the accuracy and efficacy of gene editing methods. AAV vectors play a crucial role in developing such therapies by safely and efficiently delivering therapeutic genes to target cells, thanks to their low immunogenicity and capacity for sustained gene expression. For example, IQVIA, a US-based provider of advanced analytics and technology solutions for the life sciences industry, reported that global spending on cell and gene therapies hit $5.9 billion in 2023, marking a 38% rise from 2022. Consequently, the rising focus on creating gene-based therapies is propelling the growth of the AAV vectors market.
Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Segmentation: How Is The Market Structured Across Key Categories?
The adeno-associated virus (avv) vectors in gene therapy market covered in this report is segmented –
1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy
2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo
3) By Scale of Operation: Preclinical, Clinical, Commercial
4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area
Subsegments:
1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders
2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering
3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine
Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Innovation Trends: Which Developments Are Transforming The Industry?
Leading firms active in the adeno-associated virus (AAV) vector segment of the gene therapy market are concentrating their efforts on cutting-edge innovation, particularly customized vector diversity for assay flexibility, aiming to boost target tissue specificity, enhance therapeutic efficacy, and speed up development of tailored gene therapies across a range of indications. This concept involves employing different AAV serotypes or constructs to facilitate a variety of analytical tests and therapeutic uses. As an example, Charles River Laboratories, a pharmaceutical company headquartered in the United States, launched novel reference materials for AAV and lentiviral vectors (LVV) in May 2024. Designed to meet the expanding requirements of cell and gene therapy (CGT) development, these materials enable a more seamless shift from initial research stages to GMP-grade manufacturing. The portfolio contributes to process standardization and enhanced consistency in producing viral vectors. This introduction tackles a critical obstacle in scaling CGT programs for clinical and commercial application.
Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Competitive Landscape And Leading Companies
Major companies operating in the adeno-associated virus (avv) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.
Access The Complete Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Report:
Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2025. The regions covered in the adeno-associated virus (avv) vectors in gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
